Vanguard Group Inc. Buys 10,197 Shares of Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Vanguard Group added 10,197 shares in Q4 and now owns 5,917,142 shares of Jazz Pharmaceuticals — about 9.74% of the company, valued at roughly $1.006 billion at the end of the period.
• Insiders have been selling recently: Director Bruce C. Cozadd sold 6,000 shares (~$1.143M) and the CAO sold 1,287 shares, with insiders disposing of 74,015 shares worth $14.18M in the last 90 days (corporate insiders now own 4.30%).
• Several analysts raised price targets in late February, leaving a MarketBeat consensus rating of Moderate Buy and a consensus target price of $216.87 (1 Strong Buy, 14 Buy, 2 Hold, 1 Sell).

Vanguard Group Inc. boosted its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 0.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,917,142 shares of the specialty pharmaceutical company's stock after purchasing an additional 10,197 shares during the period. Vanguard Group Inc. owned about 9.74% of Jazz Pharmaceuticals worth $1,005,914,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Dimensional Fund Advisors LP lifted its stake in shares of Jazz Pharmaceuticals by 11.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,836,652 shares of the specialty pharmaceutical company's stock worth $373,855,000 after acquiring an additional 298,815 shares during the period. Ruffer LLP acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $2,425,000. Essex Investment Management Co. LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $2,697,000. Sequoia Financial Advisors LLC acquired a new stake in shares of Jazz Pharmaceuticals in the 3rd quarter worth approximately $605,000. Finally, JPMorgan Chase & Co. lifted its stake in shares of Jazz Pharmaceuticals by 8.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,867,159 shares of the specialty pharmaceutical company's stock worth $246,092,000 after acquiring an additional 145,865 shares during the period. Institutional investors own 89.14% of the company's stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of the firm's stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $190.50, for a total value of $1,143,000.00. Following the completion of the transaction, the director directly owned 384,682 shares in the company, valued at $73,281,921. This trade represents a 1.54% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Patricia Carr sold 1,287 shares of the firm's stock in a transaction dated Monday, March 9th. The stock was sold at an average price of $182.94, for a total transaction of $235,443.78. Following the completion of the transaction, the chief accounting officer owned 6,512 shares of the company's stock, valued at approximately $1,191,305.28. The trade was a 16.50% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 74,015 shares of company stock valued at $14,180,486. Corporate insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

JAZZ has been the subject of a number of research analyst reports. Bank of America upped their price target on shares of Jazz Pharmaceuticals from $263.00 to $275.00 and gave the stock a "buy" rating in a research note on Wednesday, February 25th. Royal Bank Of Canada upped their price target on shares of Jazz Pharmaceuticals from $191.00 to $195.00 and gave the stock an "outperform" rating in a research note on Wednesday, February 25th. Morgan Stanley upped their price target on shares of Jazz Pharmaceuticals from $225.00 to $226.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. Truist Financial raised shares of Jazz Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, March 25th. Finally, Wells Fargo & Company lifted their price objective on shares of Jazz Pharmaceuticals from $235.00 to $250.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 25th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus target price of $216.87.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $202.72 on Friday. The firm's 50 day moving average is $189.65 and its 200-day moving average is $170.60. The stock has a market capitalization of $12.72 billion, a P/E ratio of -33.96, a P/E/G ratio of 0.35 and a beta of 0.27. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.86 and a quick ratio of 1.67. Jazz Pharmaceuticals PLC has a 12-month low of $97.50 and a 12-month high of $207.48.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The specialty pharmaceutical company reported $6.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.49 by $0.15. The company had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.17 billion. Jazz Pharmaceuticals had a negative net margin of 8.35% and a positive return on equity of 6.87%. The business's revenue was up 8.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $6.51 EPS. Equities research analysts anticipate that Jazz Pharmaceuticals PLC will post 20.65 EPS for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.